FDA Clears Versius Plus for Six Gynaecological Procedures

The U.S. Food and Drug Administration cleared CMR Surgical's Versius Plus system on October 23, 2026, for six benign gynaecological procedures, extending the Cambridge, UK-based company's American footprint beyond the cholecystectomy indication it secured in December 2025. The 510(k) clearance covers total hysterectomy, oophorectomy, salpingectomy, adnexectomy, ovarian cystectomy and lysis of adhesions in patients 22 and older, based on a 45-procedure clinical study in which every case was completed without conversion to another surgical approach.

For hospital procurement committees watching the US soft-tissue robotics market, the clearance answers a narrow but consequential question: can a non-da Vinci platform earn indication-by-indication access to gynaecology, one of the highest-volume specialties in minimally invasive surgery, without the installed base that Intuitive Surgical has spent two decades building. CMR's answer, delivered through a sequence of filings rather than a single broad approval, suggests the company is treating the FDA relationship as an iterative negotiation rather than a one-time hurdle.

Gynaecological procedures represent one of the largest volume pools in US minimally invasive surgery, with hysterectomy alone performed on hundreds of thousands of patients annually across American hospitals. That scale is precisely why the specialty has become a proving ground for every robotic surgery vendor seeking a second or third foothold beyond general surgery, and why a clearance covering six distinct procedure types, rather than a single narrow use case, is a meaningfully larger opportunity than CMR's earlier cholecystectomy indication alone.

A Narrower Clearance Than It First Appears

The gynaecology clearance comes with a specific carve-out that procurement teams should register before assuming full interchangeability with incumbent systems. The FDA clearance excludes use of CMR's Monopolar Curved Scissors in these gynaecological procedures, a contraindication the company says reflects data still under evaluation for a future submission. In the interim, surgeons using Versius Plus for hysterectomy or oophorectomy are directed toward Bipolar Graspers, a monopolar hook, and non-energised Curved Scissors instead.

That distinction matters operationally. A surgical team accustomed to a single energy-delivery instrument across procedure types will need to adjust technique and instrument selection specifically for gynaecological cases, a detail that typically surfaces during the credentialing and training phase rather than in a press release. CMR has not published a timeline for closing that instrument gap, telling reporters only that it continues to evaluate monopolar scissors data for gynaecology and will work with hospitals and surgeons on introducing the cleared configuration.

Versius Plus itself is CMR's second-generation platform, built around a compact, modular bedside unit design that the company positions as easier to move between operating rooms than fixed-cart competitors. The system received its own 510(k) clearance for cholecystectomy in December 2025 and made its US clinical debut alongside CMR's announcement in March 2026 that more than 45,000 patients had been treated globally on the Versius family of systems. The gynaecology clearance is therefore not a new product launch but the next indication layered onto a platform CMR has been building toward a broader US soft-tissue surgery footprint since its original Versius system earned FDA marketing authorization in October 2024.

The Stryker Relationship Changes the Commercial Calculus

The timing sits ten days after CMR announced a strategic alliance with Stryker on October 12, under which Stryker took a reported US$400 million stake and assumed leadership of CMR's US sales organization. That arrangement reframes what a narrow indication clearance means commercially. Rather than CMR building a standalone US sales and surgeon-training infrastructure specialty by specialty, each new FDA clearance now feeds into a distribution relationship with a company that already has deep operating-room relationships across general surgery, orthopaedics and other service lines.

For a hospital system evaluating a second robotic platform alongside an existing da Vinci fleet, that changes the procurement conversation from "does CMR have a service and training network in gynaecology" to "does Stryker's existing surgical sales infrastructure extend coverage into this indication." It is a meaningfully different risk profile for a chief medical officer or supply chain director to underwrite, and it is the kind of structural detail that a narrow focus on the clearance date alone would miss.

How the Competitive Field Looks From a Gynaecology Operating Room

Gynaecological surgery is one of the few soft-tissue specialties where multiple robotic platforms now compete for the same procedure volume. Intuitive Surgical's da Vinci systems have carried broad gynaecological indications for more than a decade and remain the default purchase for most US hospital systems building a first robotic surgery program. Medtronic's Hugo platform, which RobotAIGeek covered when it secured its first FDA-cleared energy instrument, is pursuing a similar indication-by-indication strategy aimed at hospitals looking for a second vendor to negotiate service contracts against. CMR's gynaecology clearance places Versius Plus in that same contest, but with a narrower instrument set than either competitor currently offers for the specialty.

That narrower instrument set is the central fact a buying committee needs to weigh. A hospital adding a second robotic vendor typically does so to gain negotiating leverage on service contracts and to diversify supply risk, not because surgeons want to relearn instrument selection for procedures they already perform confidently on an existing platform. Versius Plus's modular, cart-light design is a genuine differentiator for facilities with cramped operating rooms or multiple suites sharing one system, since the bedside units can move between rooms more easily than a fixed-cart competitor. But that mobility advantage only converts into purchase orders if the instrument set reaches parity quickly enough that surgical teams are not asked to accept a persistent limitation in exchange for better room utilization.

Why Indication-by-Indication Filing Is the Strategy, Not a Delay

CMR's sequencing, cholecystectomy first, then gynaecology, with monopolar energy devices still pending, reflects a deliberate approach common among robotic surgery entrants without an incumbent's regulatory history: narrow the clinical claim to match the available data rather than seek one broad soft-tissue authorization and risk a longer review cycle. Intuitive Surgical's da Vinci systems carry gynaecological indications built over years of incremental filings of their own, and CMR's path mirrors that precedent rather than attempting to leapfrog it.

The approach carries a clear tradeoff. Hospitals evaluating Versius Plus for gynaecology today are buying into a system whose instrument set for that specialty is still incomplete, which means initial procedure volume will likely concentrate among surgeons willing to adapt technique around the available energy instruments. CMR's own clinical study, 45 procedures with zero conversions, is a reassuring safety signal but a small sample against which to project outcomes across the thousands of annual hysterectomies performed at a typical high-volume US hospital system.

The Stryker Question Procurement Teams Are Not Yet Asking

Most coverage of the October 12 Stryker alliance focused on the headline investment figure and the leadership change in CMR's US sales organization. The more useful question for a hospital supply chain director is what Stryker's existing footprint actually unlocks at the indication level. Stryker's sales teams already carry long-standing relationships with the same general surgery and gynaecology service lines that would evaluate a Versius Plus purchase, built through decades of selling surgical navigation, joint replacement and other hospital capital equipment. If that relationship converts into faster surgeon trials and credentialing support for the new gynaecology indication, CMR's clearance will translate into procedure volume faster than a comparable clearance would have under CMR's prior, smaller US sales operation. If it does not, the clearance remains a regulatory milestone without the commercial infrastructure to capitalize on it quickly.

Hospitals currently running a request-for-proposal process that includes Versius Plus should treat the instrument limitation and the Stryker integration as linked questions rather than separate line items. A system willing to accept the current energy-device gap in exchange for early access and favorable service terms during Stryker's integration period faces a different risk calculus than one that waits for full instrument parity before committing capital. Neither choice is obviously correct, but conflating the two into a single yes-or-no purchase decision is where procurement analysis in this category tends to go wrong.

What Buyers Should Watch Next

The more consequential signal is not this clearance alone but what follows it. If CMR secures monopolar scissors clearance for gynaecology within the next filing cycle, it closes the instrument gap that currently separates Versius Plus from a fully interchangeable gynaecological robotic platform. If that filing stalls, hospitals will have to weigh a platform with meaningfully more restricted energy options for one of its newest indications. Procurement teams running multi-year capital plans should treat the December 2025 cholecystectomy clearance and this gynaecology clearance as data points in a trajectory, not as evidence that Versius Plus has reached indication parity with established competitors.

The quotable fact for anyone sizing up this market: CMR went from its first US marketing authorization in October 2024 to a second specialty indication, backed by a major strategic distribution partner, in exactly two years, a pace that signals the company is treating the FDA as a sequential unlock mechanism for US market entry rather than a single gate it needed to clear once.

CMR Surgical was founded in 2014 and is headquartered in Cambridge, UK, as a privately held company backed by an international shareholder base. This analysis synthesizes CMR Surgical's public regulatory disclosures and recent corporate announcements.

This article is for general information purposes only and does not constitute investment, financial, legal or professional advice.